Uncategorized Archives - Page 23 of 87 - PsychedelicNewsWire (PNW)

MondaySep 27, 2021 10:58 am

Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) Looks Optimally Positioned to Benefit From Continued Growth Within the Psychedelic Wellness Sector

Delic has positioned itself as a leading psychedelic wellness platform, with businesses spanning all corners within the sector Delic’s latest announced acquisition will make it the largest chain of operating psychedelic wellness clinics in the US The psychedelic wellness sector has enjoyed robust growth as of late, following the FDA’s move towards granting psilocybin “breakthrough therapy” status in 2018 Denver and Oakland have been among the first US cities to decriminalize the use of psilocybin mushrooms with California currently studying whether to follow suit The psychedelic drugs market is expected to reach a size of $10.75 billion by 2027 When…

FridaySep 24, 2021 1:00 pm

California Activists Receive Approval to Gather Signatures for Psilocybin Legalization Measure

Activists in the state of California have received approval to start gathering signatures for a measure to legalize magic mushrooms. Last week, the office of the attorney general released a title and summary for the initiative, which activists are hoping to include in next year’s ballot. The group behind the proposal, Decriminalize California, is now focused on collecting 623,212 signatures that will allow the initiative, which would legalize the sale of psilocybin under California state law to make the ballot. Advocates are required to gather registered voter signatures in the next 180 days in order to qualify the measure for…

ThursdaySep 23, 2021 2:00 pm

Researchers Focus on Better Understanding Ketamine’s Mechanism of Action

Ketamine has been used for years as an anesthetic and as a horse sedative. In the early 2000s, researchers discovered that the psychedelic possessed antidepressant properties. This finding prompted research into the medication, with the U.S. FDA recently approving a ketamine-based nasal spray indicated for the management of depression. During the 2021 Festival of Neuroscience at the British Neuroscience Association, a whole session was devoted to talks on new research on understanding the substance’s mechanism of action and its possible use as an alcohol use disorder treatment. Professor Emma Robinson of the University of Bristol, who was the co-chair of…

ThursdaySep 23, 2021 9:03 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Continues to Increase Awareness of Novel Psychedelic Drug Candidates

Pharmaceutical company Tryp Therapeutics is preparing for clinical trials evaluating synthetic formulations of psilocybin to treat medical conditions with underpinning neurological causes The clinical trials planned are being conducted in partnership with research teams at the University of Florida and the University of Michigan Tryp executives have been meeting with investors at select conferences recently to increase awareness, including the just-completed Sept. 21 presentation at Oppenheimer’s Fall Healthcare Life Sciences & MedTech Summit The company expects to initiate Phase 2a trials to begin before the end of the year for treating certain eating disorders, with Phase 2b trials to follow…

WednesdaySep 22, 2021 1:45 pm

Canadian Company Takes Advantage of Psychedelics Popularity with Their New Beverage

Psychedelic Water is focused on capitalizing on the popularity of psychedelics with its kava-based drink. Kava is popular in the South Pacific, particularly in Fiji, which has it as its national drink. The Canadian beverage company asserts that its Psychedelic Water beverage is the first psychedelic blend of green tea leaf extract, damiana leaf and kava root in the world. The beverage isn’t hallucinogenic and has been developed to produce a calming sensation for a mood-boosting experience. The beverage is sponsored by Keith Stein and Pankaj Gogia, who discussed the potential for a psychedelic-based beverage after meeting through a mutual…

TuesdaySep 21, 2021 2:30 pm

Study Finds Intravenous Ketamine May Be Safely Used for Depression in Adolescents

A study has found that intravenous ketamine is effective in reducing symptoms of depression in the short term and is well tolerated among adolescents suffering from depression. Yale Child Study Center’s Jennifer B. Dwyer and her fellow researchers stated that case reports proposed early potential effectiveness of intranasal ketamine in bipolar depression and intravenous ketamine in depression in adolescents. The researchers also revealed that an intravenous (“IV”) ketamine open-label trial that was conducted recently, which recruited 13 adolescents with treatment-resistant depression, also proposed that ketamine could be efficacious in this population. However, the lack of placebo in the trial complicated…

MondaySep 20, 2021 2:00 pm

Study Finds Way to Explain LSD’s Potency

LSD is among the most potent and longest-lasting psychedelic substances. Until recently, scientists hadn’t fully understood why LSD’s effects lingered for more than 12 hours. However, a study has found that how the drug fits into brain receptors can help explain the drug’s longevity. The study was published in “Cell.” The study’s senior co-author Bryan Roth stated that many individuals who ingested LSD weren’t aware of how long its effects would last. For their study, researchers from Roth’s laboratory captured crystallography images of an LSD molecule that was bound to the serotonin receptors in the brain. Crystallography images are images…

FridaySep 17, 2021 2:00 pm

Study Finds Ketamine Safe for Use in Managing Treatment-Resistant Depression

New research conducted by researchers from the Federal University of Bahia has found that ketamine and esketamine may be used safely as a treatment for depression. Ketamine is a synthetic compound used as an anesthesia drug while esketamine is an anesthetic that has been used to manage treatment-resistant depression. Ketamine is sometimes abused as a club drug and is popularly referred to as Special K and K in this scenario. Various studies suggest that low doses of ketamine offer rapid antidepressant effects, improving a patient’s mood within 24 hours. Esketamine has been shown to possess similar benefits. A version of…

FridaySep 17, 2021 9:00 am

Differentiated Approach in Psychedelics Boosts Confidence in Upcoming Clinical Trials for Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF)

Pharmaceutical company Tryp Therapeutics is pursuing novel solutions to medical conditions with unmet needs, working to establish the efficacy and safety of the company’s trademarked synthetic psychedelic drug candidate The company’s products — TRP-8802 and TRP-8803 — aim to provide new therapies for select eating disorders with specific neurological causes, as well as pain and addition concerns Tryp is preparing Phase 2a and Phase 2b clinical trials and expects to advance its Psilocybin-for-Neuropsychiatric Disorders (“PFN”) platform in conjunction with research teams at the University of Florida and the University of Michigan The DEA recently recommended a significant increase in cannabis…

ThursdaySep 16, 2021 2:00 pm

Researchers Find That Encounters with ‘Higher Power’ May Improve Mental Health

Over the millennia, different individuals have admitted to experiencing deeply moving religious encounters, sometimes spontaneously and sometimes while under the influence of psychedelics, including ayahuasca or psilocybin. Researchers at Johns Hopkins Medicine recently conducted a survey involving individuals who had admitted to experiencing personal encounters with a higher power. The survey results indicated that more than half of the individuals who identified as atheists stopped identifying as such so after their experience, regardless of whether it was brought on while under the influence of a psychedelic or if it was spontaneous. Additionally, most of the respondents credited the lasting positive…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000

Category: Uncategorized